By a News Reporter-Staff News Editor at Biotech Week -- New research on Oncology is the subject of a report. According to news reporting from Thessaloniki, Greece, by NewsRx journalists, research stated, "Angiogenesis affects both wound healing and malignant cell growth through nutrients and oxygen. Vascular endothelial growth factor (VEGF) is the most important element involved in this complex process."
The news correspondents obtained a quote from the research from Aristotle University, "Inhibition of VEGF influences angiogenesis and may restrict tumor growth and metastatic ability. Modern anti-angiogenic therapy is based on this theory. Bevacizumab is a recombinant humanized monoclonal antibody (immunoglobulin G1) which binds with VEGF-A forming a large molecule. It can not be bound with VEGF tyrosine kinase receptors preventing VEGF-A incorporation; thus its activity is inhibited inducing blockage of VEGF-mediated angiogenesis. Bevacizumab, in combination with chemotherapy or other novel targeted therapeutic agents, is currently used more frequently in clinical practice, mainly for managing advanced colorectal cancer. It is also used for managing other malignancies, such as breast cancer, pancreatic cancer, prostate cancer, non small-cell lung cancer, metastatic renal carcinoma and ovarian tumors. Although it is generally considered a safe treatment, there are reports of some rare side effects which should be taken into account."
According to the news reporters, the research concluded: "Recent experiments in rats and mice show promising results with a wider therapeutic range."
For more information on this research see: Role of bevacizumab in colorectal cancer growth and its adverse effects: A review. World Journal of Gastroenterology, 2013;19(31):5051-5060. World Journal of Gastroenterology can be contacted at: Baishideng Publ Grp Co Ltd, Room 1701, 17-F, Henan Building, No. 90, Jaffe Rd, Wanchai, Hong Kong 100025, Peoples R China. (Baishideng Publishing Group - www.wjgnet.com/; World Journal of Gastroenterology - www.wjgnet.com/1007-9327/current.htm)
Our news journalists report that additional information may be obtained by contacting E.T. Pavlidis, Aristotle University, Hippocrat Hosp, Sch Med, Surg Propedeut Dept. of 2, Thessaloniki 54642, Greece (see also Oncology).
Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Drugs, Greece, Europe, Oncology, Colorectal, Bevacizumab, Thessaloniki, Angiogenesis, Chemotherapy, Colon Cancer, Therapeutics, Protein Kinases, Gastroenterology, Membrane Proteins, Angiogenic Proteins, Phosphotransferases, Growth Factor Receptors, VEGF - VEGFR Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC